179 related articles for article (PubMed ID: 26863637)
1. Regression/eradication of gliomas in mice by a systemically-deliverable ATF5 dominant-negative peptide.
Cates CC; Arias AD; Nakayama Wong LS; Lamé MW; Sidorov M; Cayanan G; Rowland DJ; Fung J; Karpel-Massler G; Siegelin MD; Greene LA; Angelastro JM
Oncotarget; 2016 Mar; 7(11):12718-30. PubMed ID: 26863637
[TBL] [Abstract][Full Text] [Related]
2. Regulated ATF5 loss-of-function in adult mice blocks formation and causes regression/eradication of gliomas.
Arias A; Lamé MW; Santarelli L; Hen R; Greene LA; Angelastro JM
Oncogene; 2012 Feb; 31(6):739-51. PubMed ID: 21725368
[TBL] [Abstract][Full Text] [Related]
3. A Synthetic Cell-Penetrating Dominant-Negative ATF5 Peptide Exerts Anticancer Activity against a Broad Spectrum of Treatment-Resistant Cancers.
Karpel-Massler G; Horst BA; Shu C; Chau L; Tsujiuchi T; Bruce JN; Canoll P; Greene LA; Angelastro JM; Siegelin MD
Clin Cancer Res; 2016 Sep; 22(18):4698-711. PubMed ID: 27126996
[TBL] [Abstract][Full Text] [Related]
4. Targeting ATF5 in Cancer.
Angelastro JM
Trends Cancer; 2017 Jul; 3(7):471-474. PubMed ID: 28718401
[TBL] [Abstract][Full Text] [Related]
5. Expression and targeting of transcription factor ATF5 in dog gliomas.
York D; Sproul CD; Chikere N; Dickinson PJ; Angelastro JM
Vet Comp Oncol; 2018 Mar; 16(1):102-107. PubMed ID: 28480569
[TBL] [Abstract][Full Text] [Related]
6. miR-141-3p functions as a tumor suppressor modulating activating transcription factor 5 in glioma.
Wang M; Hu M; Li Z; Qian D; Wang B; Liu DX
Biochem Biophys Res Commun; 2017 Sep; 490(4):1260-1267. PubMed ID: 28595907
[TBL] [Abstract][Full Text] [Related]
7. A genome-wide RNA interference screen reveals an essential CREB3L2-ATF5-MCL1 survival pathway in malignant glioma with therapeutic implications.
Sheng Z; Li L; Zhu LJ; Smith TW; Demers A; Ross AH; Moser RP; Green MR
Nat Med; 2010 Jun; 16(6):671-7. PubMed ID: 20495567
[TBL] [Abstract][Full Text] [Related]
8. Interference with ATF5 function enhances the sensitivity of human pancreatic cancer cells to paclitaxel-induced apoptosis.
Hu M; Wang B; Qian D; Li L; Zhang L; Song X; Liu DX
Anticancer Res; 2012 Oct; 32(10):4385-94. PubMed ID: 23060563
[TBL] [Abstract][Full Text] [Related]
9. An activating transcription factor 5-mediated survival pathway as a target for cancer therapy?
Sheng Z; Evans SK; Green MR
Oncotarget; 2010 Oct; 1(6):457-460. PubMed ID: 21311102
[TBL] [Abstract][Full Text] [Related]
10. The transcription factor ATF5: role in cellular differentiation, stress responses, and cancer.
Sears TK; Angelastro JM
Oncotarget; 2017 Oct; 8(48):84595-84609. PubMed ID: 29137451
[TBL] [Abstract][Full Text] [Related]
11. The neuroprotective transcription factor ATF5 is decreased and sequestered into polyglutamine inclusions in Huntington's disease.
Hernández IH; Torres-Peraza J; Santos-Galindo M; Ramos-Morón E; Fernández-Fernández MR; Pérez-Álvarez MJ; Miranda-Vizuete A; Lucas JJ
Acta Neuropathol; 2017 Dec; 134(6):839-850. PubMed ID: 28861715
[TBL] [Abstract][Full Text] [Related]
12. The transcription factor ATF5 is widely expressed in carcinomas, and interference with its function selectively kills neoplastic, but not nontransformed, breast cell lines.
Monaco SE; Angelastro JM; Szabolcs M; Greene LA
Int J Cancer; 2007 May; 120(9):1883-90. PubMed ID: 17266024
[TBL] [Abstract][Full Text] [Related]
13. Human cytomegalovirus inhibits apoptosis by regulating the activating transcription factor 5 signaling pathway in human malignant glioma cells.
Wang T; Qian D; Hu M; Li L; Zhang L; Chen H; Yang R; Wang B
Oncol Lett; 2014 Sep; 8(3):1051-1057. PubMed ID: 25120656
[TBL] [Abstract][Full Text] [Related]
14. HSP70 protein promotes survival of C6 and U87 glioma cells by inhibition of ATF5 degradation.
Li G; Xu Y; Guan D; Liu Z; Liu DX
J Biol Chem; 2011 Jun; 286(23):20251-9. PubMed ID: 21521685
[TBL] [Abstract][Full Text] [Related]
15. Human cytomegalovirus immediate-early protein promotes survival of glioma cells through interacting and acetylating ATF5.
Hu M; Wang B; Qian D; Wang M; Huang R; Wei L; Li L; Zhang L; Liu DX
Oncotarget; 2017 May; 8(19):32157-32170. PubMed ID: 28473657
[TBL] [Abstract][Full Text] [Related]
16. Selective destruction of glioblastoma cells by interference with the activity or expression of ATF5.
Angelastro JM; Canoll PD; Kuo J; Weicker M; Costa A; Bruce JN; Greene LA
Oncogene; 2006 Feb; 25(6):907-16. PubMed ID: 16170340
[TBL] [Abstract][Full Text] [Related]
17. Activating Transcription Factor 5 Promotes Neuroblastoma Metastasis by Inducing Anoikis Resistance.
Banerjee D; Boboila S; Okochi S; Angelastro JM; Kadenhe-Chiweshe AV; Lopez G; Califano A; Connolly EP; Greene LA; Yamashiro DJ
Cancer Res Commun; 2023 Dec; 3(12):2518-2530. PubMed ID: 38014922
[TBL] [Abstract][Full Text] [Related]
18. DNA methylation level of promoter region of activating transcription factor 5 in glioma.
Hua XM; Wang J; Qian DM; Song JY; Chen H; Zhu XL; Zhou R; Zhao YD; Zhou XZ; Li L; Zhang L; Song XX; Wang B
J Zhejiang Univ Sci B; 2015 Sep; 16(9):757-62. PubMed ID: 26365117
[TBL] [Abstract][Full Text] [Related]
19. Study of the biodistribution of fluorescein in glioma-infiltrated mouse brain and histopathological correlation of intraoperative findings in high-grade gliomas resected under fluorescein fluorescence guidance.
Diaz RJ; Dios RR; Hattab EM; Burrell K; Rakopoulos P; Sabha N; Hawkins C; Zadeh G; Rutka JT; Cohen-Gadol AA
J Neurosurg; 2015 Jun; 122(6):1360-9. PubMed ID: 25839919
[TBL] [Abstract][Full Text] [Related]
20. ELF1 Transcription Factor Enhances the Progression of Glioma via ATF5 promoter.
Hu M; Li H; Xie H; Fan M; Wang J; Zhang N; Ma J; Che S
ACS Chem Neurosci; 2021 Apr; 12(7):1252-1261. PubMed ID: 33720698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
